Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.51 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | DRD3 | P35462 | 4/20 | 0.43 |
| ▸ | DRD1 | P21728 | 4/20 | 0.42 |
| ▸ | DRD5 | P21918 | 4/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anilopam SCHEMBL120849 | 0.99 | HRH3 (0.50) | HRH3DRD2DRD3DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL11455605 | 0.87 | HRH3 (0.51) | HRH3DRD2DRD3DRD1DRD5 | |
| SCHEMBL10659360 | 0.83 | CA1 (0.49) | HRH3DRD2DRD3DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL10663782 | 0.82 | CA1 (0.48) | HRH3DRD2DRD1DRD4CA1 | |
| SCHEMBL8789538 | 0.79 | ABCB1 (0.63) | HRH3SIGMAR1ADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL11457241 | 0.78 | DRD1 (0.52) | HRH3DRD2DRD3DRD1DRD5 | |
| SCHEMBL8789784 | 0.76 | ABCB1 (0.63) | DRD1DRD5SIGMAR1ABCB1 | |
| Hydrochloric Acid SCHEMBL11476372 | 0.75 | DRD2 (0.48) | DRD2DRD3DRD1DRD5DRD4 | |
| Hydrochloric Acid SCHEMBL11457812 | 0.74 | HRH3 (0.46) | HRH3DRD2DRD3DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL11457319 | 0.73 | DRD2 (0.54) | DRD2DRD3DRD1DRD5DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250251323-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE | 2025-08-07 | — | — | US | disclosed |
| WO-2025128946-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4536139-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | The Methodist Hospital (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536138-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | The Methodist Hospital (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4507825-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | Board of Regents, The University of Texas System (US) | 2025-02-19 | — | — | EP | disclosed |
| WO-2024211329-A2 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024044315-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023244797-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL SYSTEM (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244821-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL SYSTEM (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023200850-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-10-19 | — | — | WO | disclosed |
| EP-3698832-B1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | FONTEM HOLDINGS 1 BV (NL) | 2022-07-13 | — | — | EP | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3943501-A1 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES | Halozyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | HRH3 4752/4885DRD2 4691/4885DRD3 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.